Traditional Chinese medicine knocks at the door of the world

Recently, the innovative Chinese medicine Fuzheng Huayu capsule / tablet of Shanghai Modern Chinese Medicine Co., Ltd announced the results of the US phase clinical trial of Fuzheng Huayu tablet for the first time in China The study verified the efficacy, safety and effectiveness of Fuzheng Huayu tablet in the treatment of chronic hepatitis C liver fibrosis with the highest standard in the United States The US phase clinical trial of Fuzheng Huayu tablet was supported by the national science and technology support plan of the 11th Five Year Plan and the "international science and technology cooperation and exchange project" of the Ministry of science and technology of the people's Republic of China Based on the traditional theory of traditional Chinese medicine and combined with the international standard of clinical scientific research, Fuzheng Huayu has set many world first It is not only the first Chinese patent medicine in the field of liver disease to conduct clinical trials in the United States, but also the first successful model of foreign clinical research challenging the selection of refractory patients who have failed to receive western medicine treatment with high treatment difficulty It also pioneered the use of "hard end point" liver biopsy in clinical trials in the United States It not only achieved zero breakthrough in the field of liver fibrosis treatment, but also It is the first Chinese patent medicine representative to show the innovative achievements to the world experts at the international highest level medical event (American hepatology annual meeting) Fuzheng Huayu tablet was approved by FDA in 2006 The trial was led by Shanghai Modern Chinese Medicine Co., Ltd and carried out jointly by 9 authoritative medical institutions and many international famous liver experts Fuzheng Huayu tablet completed the US phase clinical trial, further consolidating its leading position in the field of liver fibrosis treatment in the world, making Fuzheng Huayu tablet is expected to be the first compound Chinese medicine approved to enter the mainstream pharmaceutical market in the United States, and will also lead other independent innovation Chinese medicine in China to the international stage.